Cencora Inc.
COR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for COR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$52.89B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Mar 31, 2026.
Run Cencora Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cencora Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 23.03 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1,423
Total value held
$50.01B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 19,943,637 | $6.27B |
| vanguard capital management llc | 12,313,459 | $3.87B |
| vanguard portfolio management llc | 9,590,414 | $3.01B |
| state street corp | 9,190,551 | $2.89B |
| fmr llc | 6,686,269 | $2.10B |
| geode capital management, llc | 5,566,044 | $1.75B |
| wellington management group llp | 4,548,612 | $1.43B |
| morgan stanley | 4,531,912 | $1.42B |
| boston partners | 4,482,817 | $1.41B |
| bank of america corp /de/ | 4,138,388 | $1.30B |
Showing top 10 of 1,423 institutional holders of Cencora Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 3.0%
- Days to cover
- 3.8
- Shares short
- 5,191,933
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
COR short interestGovernance
Frequently asked questions
Who is the CEO of Cencora Inc.?
Dr. Robert P. Mauch Ph.D., PharmD is the chief executive officer of Cencora Inc. (COR).
Where is Cencora Inc. headquartered?
Cencora Inc. (COR) is headquartered in Conshohocken, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.